- Home
- FBRX vs MDXH Comparison
FBRX vs MDXH Comparison
Compare FBRX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- MDXH
- Stock Information
- Founded
- FBRX N/A
- MDXH 2003
- Country
- FBRX United States
- MDXH Belgium
- Employees
- FBRX N/A
- MDXH N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- MDXH
- Sector
- FBRX Health Care
- MDXH
- Exchange
- FBRX Nasdaq
- MDXH Nasdaq
- Market Cap
- FBRX 154.5M
- MDXH 141.1M
- IPO Year
- FBRX N/A
- MDXH 2021
- Fundamental
- Price
- FBRX $11.96
- MDXH $3.68
- Analyst Decision
- FBRX Strong Buy
- MDXH Buy
- Analyst Count
- FBRX 3
- MDXH 1
- Target Price
- FBRX $68.00
- MDXH $6.00
- AVG Volume (30 Days)
- FBRX 79.4K
- MDXH 163.1K
- Earning Date
- FBRX 11-13-2025
- MDXH 11-05-2025
- Dividend Yield
- FBRX N/A
- MDXH N/A
- EPS Growth
- FBRX N/A
- MDXH N/A
- EPS
- FBRX N/A
- MDXH N/A
- Revenue
- FBRX N/A
- MDXH $98,953,000.00
- Revenue This Year
- FBRX N/A
- MDXH $24.77
- Revenue Next Year
- FBRX N/A
- MDXH $22.21
- P/E Ratio
- FBRX N/A
- MDXH N/A
- Revenue Growth
- FBRX N/A
- MDXH 22.56
- 52 Week Low
- FBRX $4.11
- MDXH $1.35
- 52 Week High
- FBRX $28.68
- MDXH $3.91
- Technical
- Relative Strength Index (RSI)
- FBRX 59.36
- MDXH 63.08
- Support Level
- FBRX $10.11
- MDXH $3.46
- Resistance Level
- FBRX $11.57
- MDXH $3.80
- Average True Range (ATR)
- FBRX 0.84
- MDXH 0.16
- MACD
- FBRX 0.09
- MDXH -0.02
- Stochastic Oscillator
- FBRX 78.22
- MDXH 50.00
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.